Shaker Mahmud, Mashhadani Zohair I Al, Mehdi Atheer A
Department of Acceptable Analysis, Health and Medical Technical College.
Oman Med J. 2010 Oct;25(4):289-93. doi: 10.5001/omj.2010.84.
Polycystic ovary syndrome is associated with insulin resistance and obesity. Previous studies suggest that metformin by reducing hyperinsulinemia is clinically useful in the treatment of polycystic ovary syndrome. This study's Objective is to observe the role of metformin in omentin1, ghrelin, and other biochemical, clinical features within three months in hyperinsulinemic women with polycystic ovary syndrome. Another aim is to assess the decrease in hyperinsulinemia and body weight by metformin in the population.
This study was carried out at the Kamal AL-Samarai Hospital between June 2007 and March 2008. 60 women fulfilling the clinical and biochemical criteria for polycystic ovary syndrome and hyperinsulinemia were enrolled. Metformin was started at an oral dose of 850 mg/day for 3 months. Besides Body Mass Index (BMI), Waist Hip Ratio (WHR), serum omentin1, ghrelin, fasting insulin, fasting blood sugar and lipid profile levels were performed. After three months, all these parameters were assessed. Omentin1, ghrelin and insulin were measured by enzyme-linked immunosorbent assay, fasting blood glucose and lipid profile were measured by colorimetric methods.
Mean Body Mass Index and Waist Hip Ratio had significantly decreased in the 60 polycystic ovary syndrome patients after three months of Metformin therapy. Serum levels of omentin1, ghrelin and HDL-cholesterol were increased while the total cholesterol/HDL cholesterol ratio was decreased significantly. Serum concentrations of insulin, Homeostatic Model Assessment (HOMA) and HOMA ß-cell % were also decreased significantly, the present study showed a significant increase in omentin1: insulin ratio, omentin1: HOMA ratio and omentin1: HOMA ß-cell% ratio.
There was a significant an increase in omentin1: insulin ratio, omentin1: HOMA ratio and omentin1: HOMA ß-cell% ratio. These results in the present study are shown the first time, these factors may be useful in following improvements in insulin sensitivity in subjects with polycystic ovary syndrome or obesity treated with insulin sensitizers. Further studies are needed to certify these factors in other populations with these treatment or with other insulin sensitizers or when treated with diet and exercise.
多囊卵巢综合征与胰岛素抵抗和肥胖相关。既往研究表明，二甲双胍通过降低高胰岛素血症，在多囊卵巢综合征的治疗中具有临床应用价值。本研究的目的是观察二甲双胍在高胰岛素血症的多囊卵巢综合征女性患者中，三个月内对网膜素-1、胃饥饿素及其他生化指标、临床特征的作用。另一目的是评估二甲双胍在该人群中降低高胰岛素血症和体重的效果。
本研究于2007年6月至2008年3月在卡迈勒·萨马莱医院开展。招募了60名符合多囊卵巢综合征和高胰岛素血症临床及生化标准的女性。开始口服二甲双胍，剂量为850毫克/天，持续3个月。除测量体重指数（BMI）、腰臀比（WHR）外，还检测血清网膜素-1、胃饥饿素、空腹胰岛素、空腹血糖和血脂水平。三个月后，对所有这些参数进行评估。网膜素-1、胃饥饿素和胰岛素采用酶联免疫吸附测定法检测，空腹血糖和血脂采用比色法检测。
60例多囊卵巢综合征患者经三个月二甲双胍治疗后，平均体重指数和腰臀比显著降低。血清网膜素-1、胃饥饿素和高密度脂蛋白胆固醇水平升高，而总胆固醇/高密度脂蛋白胆固醇比值显著降低。血清胰岛素浓度、稳态模型评估（HOMA）及HOMAβ细胞百分比也显著降低，本研究显示网膜素-1:胰岛素比值、网膜素-1:HOMA比值和网膜素-1:HOMAβ细胞百分比比值显著升高。
网膜素-1:胰岛素比值、网膜素-1:HOMA比值和网膜素-1:HOMAβ细胞百分比比值显著升高。本研究结果首次表明，这些因素可能有助于监测接受胰岛素增敏剂治疗的多囊卵巢综合征或肥胖患者胰岛素敏感性的改善情况。需要进一步研究以在其他接受此类治疗、使用其他胰岛素增敏剂或通过饮食和运动治疗的人群中验证这些因素。
